Division of Pediatric Neurology, Department of Pediatrics, Prince Sultan Military Medical City, PO Box 7889, Riyadh 11159, Saudi Arabia.
Division of Pediatric Neurology, Department of Pediatrics, Prince Sultan Military Medical City, PO Box 7889, Riyadh 11159, Saudi Arabia.
Seizure. 2023 Apr;107:146-154. doi: 10.1016/j.seizure.2023.04.013. Epub 2023 Apr 13.
To investigate the clinical features of developmental and/or epileptic encephalopathy with spike-and-wave activation in sleep (D/EE-SWAS), its electrographic characteristics, and etiology and to compare the effects of different treatment strategies on the outcomes using a Saudi Arabian database.
This multicenter study included children with D/EE-SWAS who were evaluated between 2010 and 2020 at 11 tertiary centers. Data were collected on their baseline clinical features, etiologies, and treatment modalities. Seizure reduction, spike-wave index, and cognitive state were examined as potential therapeutic outcomes.
Ninety-one children were diagnosed with D/EE-SWAS, with a median age of 7 years (IQR: 3-5) and an almost equal sex distribution. The average age at which epilepsy was diagnosed was 3 years (IQR: 5-2). A genetic/metabolic etiology was found in 35.1% of the patients, and a structural etiology was found in 27.4%. Children with underlying genetic/metabolic diseases exhibited an earlier seizure onset (P = 0.001) than children with other etiologies. Benzodiazepines (76.6%) were the most common treatment, followed by steroids (51.9%). Sodium valproate (75%) was the most frequently used antiseizure medication, followed by levetiracetam (64.9%). Children with a later seizure onset were more likely to have better clinical responses (P = 0.046), EEG responses (P = 0.012), and cognitive outcomes (P = 0.006) than children with an earlier onset. Moreover, better seizure response and electrographic response were seen in patients with bilateral interictal discharges on the EEG than otherwise. Children had a higher likelihood of both clinical and electrographic improvement with combination therapy of benzodiazepines (P = 0.001) and steroids (P = 0.001) than with other therapies.
This study shows a higher prevalence of genetic/metabolic causes and suggests the superior efficacy of combination therapy with steroids and benzodiazepines in D/EE-SWAS. Prospective studies that strictly assess the treatment protocols and outcomes are needed.
研究睡眠中出现棘慢波爆发的发育性和/或癫痫性脑病(D/EE-SWAS)的临床特征、脑电图特征、病因,并利用沙特阿拉伯数据库比较不同治疗策略对结局的影响。
这项多中心研究纳入了 2010 年至 2020 年在 11 个三级中心接受评估的 D/EE-SWAS 患儿。收集了他们的基线临床特征、病因和治疗方式的数据。以癫痫发作减少、棘慢波指数和认知状态为潜在治疗结果进行检查。
91 名患儿被诊断为 D/EE-SWAS,中位年龄为 7 岁(IQR:3-5),性别分布几乎相等。癫痫诊断的平均年龄为 3 岁(IQR:5-2)。35.1%的患儿存在遗传/代谢病因,27.4%存在结构性病因。与其他病因相比,有潜在遗传/代谢疾病的患儿癫痫发作更早(P=0.001)。最常用的治疗药物是苯二氮䓬类(76.6%),其次是类固醇(51.9%)。丙戊酸钠(75%)是最常用的抗癫痫药物,其次是左乙拉西坦(64.9%)。癫痫发作较晚的患儿更有可能获得更好的临床反应(P=0.046)、脑电图反应(P=0.012)和认知结局(P=0.006)。此外,与其他情况相比,脑电图上存在双侧间棘波放电的患儿更有可能获得更好的癫痫发作和脑电图反应。与其他治疗方法相比,联合使用苯二氮䓬类(P=0.001)和类固醇(P=0.001)的患儿更有可能获得临床和脑电图改善。
本研究显示遗传/代谢原因的患病率更高,并提示联合使用类固醇和苯二氮䓬类治疗 D/EE-SWAS 的疗效更好。需要进行严格评估治疗方案和结局的前瞻性研究。